Vida Ventures is a next-generation life sciences investment firm founded in 2017 by a group of scientists, physicians, entrepreneurs and investors passionate about building and funding breakthroughs in biomedicine. Together we form an independent, bold investment group bound together by a simple word – life. Our mission is to bring science to life and advance transformative biomedical innovations that have the potential to make a meaningful difference for patients. Vida has a bicoastal presence and currently manages approximately $295 million.
Location: United States, Massachusetts, Boston
Employees: 11-50
Investment Type: Venture Capital
Investment Stage: Series A; Series B
Portfolio 40
| Date | Name | Website | Total Raised | Location |
| 10.06.2026 | SonoThera,... | sonothera.com | $310.75M | United Sta... |
| 26.06.2025 | Antares Th... | antaresrx.com | $177M | - |
| 26.05.2025 | Attovia Th... | attovia.com | $195M | - |
| 20.09.2024 | LB Pharmac... | lbpharma.us | - | - |
| 16.09.2024 | Halda Ther... | haldatx.com | $126M | United Sta... |
| 16.09.2024 | Third Arc ... | thirdarcbio.com | $217M | United Sta... |
| 13.04.2024 | Peloton Th... | pelotontherapeutics.com | $40.2M | - |
| 13.04.2024 | InduPro | induprotx.com | $85M | United Sta... |
| 13.04.2024 | Capstan Th... | capstantx.com | $175M | United Sta... |
| 03.11.2023 | Avalyn Pha... | avalynpharma.com | $210.5M | United Sta... |
Show more
Persons 34
| Date | First Name | Last Name | Title | Location | |||
| - | Chanel | Enz | Accounting... | - | - | - | |
| - | Rajul | Jain, M.D. | Managing D... | - | - | - | |
| - | Kate | Bechtold, ... | Senior Dir... | - | - | - | |
| - | Arie | Belldegrun... | Founder an... | - | - | - | |
| - | Helen | S. Kim, M.... | Senior Man... | - | - | - | |
| - | Jean-Phili... | (JP) Kouak... | Chief Fina... | - | - | - | |
| - | Scott | Garland | Venture Pa... | - | - | - | |
| - | Dinah | Sah, Ph.D. | - | - | - | - | |
| - | David | Chang M.D.... | Scientific... | - | - | - | |
| - | Victoria | Stephens | Senior Con... | - | - | - |
Show more
News 150
Show more
Mentions in press and media 29
| Date | Title | Description |
| 16.06.2026 | SonoThera Secures $125M: Ultrasound Reshapes Genetic Medicine | SonoThera, a biotechnology pioneer, just closed a significant Series B funding round. The South San Francisco-based firm secured $125 million. This oversubscribed financing fuels its revolutionary nonviral genetic medicine platform. The inv... |
| 10.06.2026 | SonoThera Raises $125 Million Series B To Advance Ultrasound-Mediated Genetic Medicines | SonoThera, a biotechnology company developing ultrasound-mediated nonviral genetic medicines, announced the closing of an oversubscribed $125 million Series B financing round to support the clinical advancement of its lead programs for Duch... |
| 10.06.2026 | SonoThera Raises $125M in Series B Funding | SonoThera, a South San Francisco, CA-based biotechnology company developing new genetic medicines, raised $125M in Series B funding. The round was led by Vida Ventures, with participation from ARK Invest, CureDuchenne Ventures, Leaps by Bay... |
| 04.03.2026 | Poplar Therapeutics Raises $45M in Series A Extension Funding | Poplar Therapeutics, a Cambridge, MA-based clinical-stage immunology company, raised $45M in Series A extension funding. The round was led by Janus Henderson Investors, with participation from RA Capital, SR One, Vida Ventures and affiliate... |
| 03.03.2026 | Poplar Therapeutics: $45 Million Series A Extension Raised By Immunology Company To Advance Anti-IgE Therapy PHB-050 | Poplar Therapeutics, a clinical-stage immunology company developing a new class of anti-IgE therapy for food allergy and other atopic conditions, has closed a $45 million Series A extension, bringing its total Series A financing to $95 mill... |
| 08.01.2026 | Poplar Therapeutics Raises $50M in Series A Funding | Poplar Therapeutics, Inc. (previously known as Phylaxis Bioscience), a Boston, MA-based clinical-stage immunology company, raised $50m in Series A financing. The round was led by SR One, Vida Ventures and Platanus. The company intends to us... |
| 08.01.2026 | Poplar Therapeutics Launched With $50 Million Series A To Advance Anti-IgE Therapy for Multiple Atopic Conditions | Poplar Therapeutics has launched as a clinical-stage immunology company with a $50 million Series A financing to advance PHB-050, a next-generation anti-IgE antibody being developed for food allergy and other atopic conditions such as asthm... |
| 01.12.2025 | Protego Biopharma: $130 Million Series B Funding Closed To Advance Pivotal AL Amyloidosis Program | Protego Biopharma has closed an oversubscribed $130 million Series B financing round that will accelerate its first-in-class AL amyloidosis therapeutic program into a pivotal clinical study. The round was led by Novartis Venture Fund and Fo... |
| 07.10.2025 | Langer family RNA biotech Soufflé rises with $200M and Big Pharma partners | A new RNA biotech has risen with a $200 million series A in the tank and a team of seasoned biotech chefs ready to light the burners. Soufflé Therapeutics will cook up siRNA medicines that are targeted and cell-specific, the newly hatched c... |
| 29.07.2024 | Scorpion Therapeutics: A Bold Leap in Precision Oncology | Scorpion Therapeutics is making waves in the world of cancer treatment. With a recent $150 million Series C funding round, the Boston-based biotech is poised to redefine the landscape of precision oncology. This funding is not just a financ... |
Show more